Nektar Therapeutics (ITH.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 08:01AM CEST
| Previous Close | 1.2130 |
| Open | 1.3390 |
| Bid | 1.3500 x 50000 |
| Ask | 1.3780 x 50000 |
| Day's Range | 1.3390 - 1.3390 |
| 52 Week Range | 0.3901 - 1.5460 |
| Volume | |
| Avg. Volume | 2,077 |
| Market Cap | 284.046M |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
- PR Newswire
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata.
- PR Newswire
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023.
© 2024 Yahoo. All rights reserved.